Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, FDA

Interson's Latest FDA 510(k) Clearance Just Made The Future Of Ultrasound Healthcare More Accessible


PLEASANTON, Calif., June 13, 2017 /PRNewswire/ -- Interson announced today they have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market their SiMPLi Series ultrasound array probes for medical applications.  Interson has been the market leader in open-architecture USB ultrasound imaging products since 2007.

Interson's new SiMPLi Series portable and handheld diagnostic ultrasound imaging solution for vascular access.  Ultrasound probe plugs directly into your laptop or tablet via USB connection.

Interson's new linear and convex array probes enable medical professionals to use Windows tablets and laptops to display real-time ultrasound images at resolution and detail that were, until now, only available on high-end ultrasound systems. The new SiMPLi Series probes are lightweight, handheld and can easily be carried to any patient location.  The SiMPLi Series probes provide such ease of use that now every medical professional can benefit.  Simply connect the USB probe cable to a Windows computer to view real-time, high-resolution ultrasound images.

"These new array probes continue on our company vision to bring affordable, high-quality ultrasound imaging to every medical professional.  SiMPLi Series is truly a portable, bedside ultrasound solution.  We are proud to keep pushing the market forward on performance and practicality while also driving the cost of healthcare lower."   Roman Solek, President & CEO

Interson's next-generation USB probes provide the image quality necessary for a wide variety of ultrasound diagnostic applications: (For image examples follow @simpliinterson on Twitter and @simpliultrasound on Facebook)

Interson's open architecture solutions provide the capabilities and features that previously could only be addressed by more expensive, proprietary closed-architecture solutions.  SiMPLi Series portable ultrasound imaging solutions can be quickly and easily brought to the patient, making point-of-care diagnostic medical imaging more timely and convenient.  With a history of innovations recognized by the International Academy of Science, the new SiMPLi Series aims to follow by extending ultrasound diagnostic healthcare to the fingertips of all medical professionals. 

Interson Corporation, an ISO certified, privately held corporation located in Silicon Valley, is a leading U.S. manufacturer of ultrasound imaging solutions.  Ultrasound systems using Interson products have been installed in offices, hospitals, and clinics around the world since 1989. Interson ultrasound imaging probes are designed and manufactured in the U.S.A. and have FDA 510(k) clearance, a CE mark, Japan PAL NINSHO approval, and a medical device license from Health Canada.  

Contact: Gregory DePaco  Phone: 925-462-4948  Email: [email protected]
https://www.interson.com

 

SOURCE Interson


These press releases may also interest you

at 08:16
Canadian health care providers now have access to clinical tools and resources they need to better support older adults experiencing...

at 08:15
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio?quity Europe (12-14 May). The...

at 08:15
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety...

at 08:15
Nuvation Bio Inc. , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms....

at 08:15
Axiom Health, a leading provider of data analytics solutions for the medical device industry, today announced the appointments of Russell "Rusty" Lewis as Chief Executive Officer (CEO) and Jim Best as Chief Commercial Officer (CCO). These...

at 08:15
GlobeStar Therapeutics Corporation (GSTC), is a clinical stage pharmaceutical company focused on advancing new therapies for Multiple Sclerosis (MS) and other neurological diseases, including but not limited to Rheumatoid Arthritis (RA), released on...



News published on and distributed by: